Phaseline

Companies › Shanghai Allink Biotherapeutics

Shanghai Allink Biotherapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ALK201–Phase 1Advanced CancerOct 2027
ALK202–Phase 1Advanced CancerDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06656390ALK201Phase 1Advanced CancerOncologyOct 2027
NCT06707610ALK202Phase 1Advanced CancerOncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.